A Revolutionary Leap: Bridging The Gap in Antibiotic Resistance Against Pneumonia
Abstract
Nafithromycin is India's first indigenous antibiotic designed to treat community-acquired bacterial pneumonia (CABP), a major health concern, especially for the elderly and those with underlying health issues. CABP is one of the leading causes of hospitalization, primarily caused by Streptococcus pneumoniae, although it can also involve various other bacteria. This antibiotic is a macrolide, which is known for several advantageous properties: good oral bioavailability and effective penetration of lung tissue, with a three-day course of treatment, this innovative antibiotic is ten times more effective than existing medications like azithromycin, thereby reducing recovery time. Additionally, it is safe for pediatric use and has immune-modulating effects. Its spectrum of activity includes atypical bacteria that can cause pneumonia, making it particularly useful in treating pneumococcal infections in outpatient and hospital settings. The global incidence of CABP ranges from 20 to 100 cases per 10,000 person-years, highlighting its prevalence. While many cases can be treated with oral antibiotics in outpatient settings, severe cases may require hospitalization, when there are complications or when oral treatments are ineffective. Nafithromycin is particularly important as it can address multidrug-resistant strains of both typical and atypical respiratory pathogens, including those resistant to penicillin and other macrolides. This innovative antibiotic offers a promising solution…
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.